Ertumaxomab
Monoclonal antibody | |
---|---|
Type | Trifunctional antibody |
Source | Rat/mouse hybrid |
Target | HER2/neu, CD3 |
Clinical data | |
Trade names | Rexomun |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
![]() ![]() |
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]: 35 )
References
- ^ Fresenius
- ^ ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
- ^ "2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.
Categories:
- Short description with empty Wikidata description
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies for tumors
- Immunology
- Abandoned drugs
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs